{'fraction_non_alphanumeric': 0.0455026455026455, 'fraction_numerical': 0.03333333333333333, 'mean_word_length': 5.022292993630574, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Postoperative adjuvant chemoradiation using oral capecitabine and 5-fluorouracil, cisplatin (FP) in completely resected locally advanced gastric cancer.

4141 Background: Gastric cancer is the most common cancer in Korea. Adjuvant chemoradiation has become a standard of care in United States. We attempted to evaluate the efficacy and toxicity of FP before and after postoperative chemoradiation using oral capecitabine in locally advanced gastric cancer patients.


METHODS
Patients with gastric cancer staged IIIA to IV-M0 were treated with chemoradiation after curative resection with extensive (D2) lymph node dissection. Therapy consisted of one cycle of FP (5-FU 1000 mg/m2 continuous infusion on day 1-5, cisplatin 60 mg/m2 on day 1) followed by 4,500 cGY (180 cGy/day) to RT field with capecitabine (1,650 mg/m2/day throughout radiation). One month after completion of radiotherapy, patients received three additional cycles of chemotherapy.


RESULTS
Twenty-one patients were enrolled and twenty patients completed chemoradiation as planned. 17 patients were man, median age was 49 (range 31-62). The patient's stage were IIIA(12), IIIB(6), and IV-M0(3). With a median follow-up of 14.2 months, two patients (9.5%) have relapsed, one in liver and the other in peritoneum. Grade 3/4 toxicity were neurtopenia 4 patients (19%), thrombocytopenia 1 patient (5%), fatigue 1 patient (5%), nausea/vomiting 1 patient (5%). There was no grade 3/4 hand foot syndrome, and no patient has developed febrile neutropenia. There has been no treatment related deaths.


CONCLUSIONS
These preliminary results suggest that postoperative regimen of FP and chemoradiation with capecitabine is a safe, well-tolerated in gastric cancer patients who have undergone a D2 dissection. Longer follow up and further studies are needed to evaluate efficacy. No significant financial relationships to disclose.